Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Other)
• Overall Status: Completed
• CT.gov ID: NCT00007813
• Collaborator: Amgen (Industry), Baxter Healthcare Corporation (Industry), Nexell Therapeutics Inc (Other)
• Enrollment: 21
• Location: 1
• Arm: 1
• Actual Duration (Months): 92.1
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of cyclophosphamide when given together with combination chemotherapy and a peripheral stem cell transplant in treating patients with malignant solid tumors.

Condition or Disease	Intervention/Treatment	Phase
Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor	Biological: filgrastim; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Procedure: autologous bone marrow transplantation; Procedure: peripheral blood stem cell transplantation	Phase 1

Detailed Description

OBJECTIVES:

• Determine whether autologous transplantation of mobilized CD34+ peripheral blood stem cells (PBSC) can provide complete hematologic reconstitution after myeloablative chemotherapy comprising etoposide (VP-16) and carboplatin (CBDCA) in patients with metastatic or recurrent rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma/primitive neuroectodermal tumor, germ cell tumors, childhood brain tumors, or hepatoblastoma.

• Determine the frequency and yield of CD34+ PBSC and granulocyte-macrophage colony-forming units (GM-CFU) that are mobilized, harvested, and purified after a single priming course of high-dose cyclophosphamide (CTX) followed by filgrastim (G-CSF).

• Correlate the number of CD34+ cells and GM-CFU in the autologous PBSC graft with time to engraftment of white blood cells, neutrophils, and platelets in these patients.

• Determine the optimal day of PBSC harvest after a single priming course of high-dose CTX and G-CSF in these patients.

• Determine whether CD34+ PBSC rescue and daily post-transplantation G-CSF decrease the time to hematopoietic recovery after high-dose VP-16 and CBDCA compared to historical results achieved in similar patients rescued with bone marrow.

• Compare the tumor cell content of marrow, mobilized blood, and purified CD34+ PBSC graft preparations.

• Determine the optimal timing of PBSC mobilization and harvest in relation to extent of prior chemotherapy in these patients.

• Determine the feasibility of a single leukapheresis for PBSC harvest in children.

• Determine the toxic effects of this regimen in these patients.

• Determine the antitumor activity of this regimen in these patients.

OUTLINE: This is a dose-escalation study of cyclophosphamide.

Mobilization/harvest: Patients receive cyclophosphamide IV over 90 minutes on day 0 and filgrastim (G-CSF) subcutaneously or IV over 30 minutes on days 2-15 or until blood counts recover. Peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells on day 15. Bone marrow is also harvested in case insufficient PBSC are harvested.

Preparative regimen/transplantation: Patients receive carboplatin IV over 1 hour and etoposide IV continuously on days -6 to -4. Cyclophosphamide is administered IV over 1 hour on days -3 and -2 or IV continuously on days -3 and -2, -4 to -2, -5 to -2, or -6 to -2. PBSC or bone marrow is reinfused on day 0.

Cohorts of 3-10 patients receive escalating doses of cyclophosphamide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose at which 20% of patients experience dose-limiting toxicity.

At least 6 additional patients receive cyclophosphamide at the MTD.

PROJECTED ACCRUAL: A minimum of 36 patients will be accrued for this study.

Study Design

• Study Type: Interventional
• Actual Enrollment: 21 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY
• Actual Study Start Date: May 31, 1997
• Actual Primary Completion Date: Feb 1, 2005
• Actual Study Completion Date: Feb 1, 2005

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm 1	Biological: filgrastim; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Procedure: autologous bone marrow transplantation; Procedure: peripheral blood stem cell transplantation

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A to 35 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

DISEASE CHARACTERISTICS:

• Histologically proven malignant solid tumor, including any of the following:

• Rhabdomyosarcoma

• Neuroblastoma

• Ewing's sarcoma/primitive neuroectodermal tumor

• Germ cell tumors

• Childhood brain tumors

• Hepatoblastoma

• Metastatic disease OR has failed at least first-line therapy

• Ineligible for higher priority protocols

PATIENT CHARACTERISTICS:

Age:

• Under 36 at transplantation

Performance status:

• Karnofsky 60-100%

Life expectancy:

• At least 8 weeks

Hematopoietic:

• Absolute neutrophil count at least 1,000/mm3

• Platelet count at least 75,000/mm3

Hepatic:

• Bilirubin no greater than 1.5 mg/dL

• Liver function tests no greater than 2 times normal OR

• No active hepatitis on liver biopsy

• No hepatitis B infection

Renal:

• Creatinine no greater than 1.5 mg/dL OR

• Glomerular filtration rate (preferably measured) greater than 60% of normal

Cardiovascular:

• Left ventricular ejection fraction at least 45%

• No active congestive heart failure

• No active arrhythmia

Pulmonary:

• Age 8 and under: clinically normal pulmonary function

• Over age 8: FEV1 and FVC at least 50% predicted

• Arterial blood gases normal and DLCO at least 50% if spirograms difficult to

• interpret due to poor patient effort, recent surgery, or pulmonary tumor

• involvement

Other:

• No mucositis or mucosal infection prior to myeloablative chemotherapy

• HIV negative

• Not pregnant

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Johns Hopkins Oncology Center	Baltimore	Maryland	United States	21231-2410

Sponsors and Collaborators

• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Amgen
• Baxter Healthcare Corporation
• Nexell Therapeutics Inc

Investigators

• Study Chair: Allen R. Chen, MD, PhD, MHS, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Documents (Full-Text)

None provided.

More Information

Publications

• Chen AR, Cohen KJ, Eby LL, et al.: Heterogenous mobilization of CD34+ blood stem cells for autologous rescue of children with poor prognosis solid tumors. [Abstract] Blood 86: 403a, 1995.
• Leung W, Chen AR, Klann RC, et al.: Tumor cells frequently detected in marrow and mobilized blood hematopoietic grafts in neuroblastoma and primitive neuroblastoma and primitive neuroectodermal tumor: purging by immunomagnetic CD34+ cell selection. [Abstract] Blood 88: A-1917, 482a, 1996.

• Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• ClinicalTrials.gov Identifier: NCT00007813
• Other Study ID Numbers: JHOC-9512; CDR0000064263; NCI-V95-0688; 94-12-23-02
• First Posted: Apr 2, 2004
• Last Update Posted: Feb 17, 2020
• Last Verified: Feb 1, 2020

• Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: recurrent childhood rhabdomyosarcoma; childhood craniopharyngioma; recurrent childhood brain tumor; disseminated neuroblastoma; stage 4S neuroblastoma; recurrent neuroblastoma; stage IV childhood liver cancer; recurrent childhood liver cancer; childhood hepatoblastoma; childhood central nervous system germ cell tumor; stage III malignant testicular germ cell tumor; recurrent malignant testicular germ cell tumor; childhood germ cell tumor; stage IV ovarian germ cell tumor; recurrent ovarian germ cell tumor; extragonadal germ cell tumor; childhood oligodendroglioma; childhood choroid plexus tumor; childhood grade III meningioma; recurrent childhood cerebellar astrocytoma; recurrent childhood cerebral astrocytoma; recurrent childhood medulloblastoma; recurrent childhood visual pathway and hypothalamic glioma; previously treated childhood rhabdomyosarcoma; metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor; recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor; recurrent childhood ependymoma; childhood teratoma; childhood malignant testicular germ cell tumor; childhood malignant ovarian germ cell tumor; childhood extragonadal germ cell tumor; recurrent childhood malignant germ cell tumor; childhood atypical teratoid/rhabdoid tumor
• Additional relevant MeSH terms: Neoplasms; Sarcoma; Liver Neoplasms; Neuroblastoma; Neoplasms, Germ Cell and Embryonal; Nervous System Neoplasms; Central Nervous System Neoplasms; Cyclophosphamide; Carboplatin; Etoposide

Study Results

No Results Posted as of Feb 17, 2020